Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 6—June 2026

Research

In Vitro Antifungal Drug Susceptibility of Feline Sporothrix schenckii Complex Isolates, Thailand, 2023–2025

Chompoonek Yurayart, Kanokporn Yingchanakiat, Amonrat Thongbai, Orawan Limsivilai, Sathidpak Nantasanti Assawarachan, Tassanee Jaroensong, and Panpicha SattasathuchanaComments to Author 
Author affiliation: Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand

Main Article

Table 4

Distribution of non-WT phenotypes and antifungal drugs with co-reduced susceptibility patterns based on itraconazole susceptibility among feline Sporothrix schenckii complex isolates in Thailand, 2023–2025 (n = 1,178)

Itraconazole susceptibility phenotype No. drugs, non-WT Itraconazole reduced susceptibility patterns Frequency Overall
WT
 0
 None
 491 (41.7)
 491 (41.7)
Non-WT 1 Itraconazole 321 (27.2) 321 (27.2)
2 Itraconazole + posaconazole 165 (14.0) 270 (22.9)
Itraconazole + amphotericin B 94 (8.0)
Itraconazole + voriconazole 7 (0.6)
Itraconazole + terbinafine 4 (0.3)
3 Itraconazole + posaconazole + amphotericin B 74 (6.3) 88 (7.5)
Itraconazole + posaconazole + terbinafine 7 (0.6)
Itraconazole + posaconazole + voriconazole 5 (0.4)
Itraconazole + voriconazole + amphotericin B 2 (0.2)
4 Itraconazole + posaconazole + amphotericin B + terbinafine 6 (0.5) 8 (0.7)
Itraconazole + posaconazole + amphotericin B + voriconazole 2 (0.2)

*Values are no. (%) except as indicated. Non-WT is defined by previously reported epidemiologic cutoff values (21) and study-specific cutoff value (for terbinafine). Non-WT, non-wild-type; WT, wild-type.

Main Article

References
  1. Oliveira  MM, Almeida-Paes  R, Gutierrez-Galhardo  MC, Zancope-Oliveira  RM. Molecular identification of the Sporothrix schenckii complex. Rev Iberoam Micol. 2014;31:2–6. DOIPubMedGoogle Scholar
  2. Chakrabarti  A, Bonifaz  A, Gutierrez-Galhardo  MC, Mochizuki  T, Li  S. Global epidemiology of sporotrichosis. Med Mycol. 2015;53:3–14. DOIPubMedGoogle Scholar
  3. Etchecopaz  A, Toscanini  MA, Gisbert  A, Mas  J, Scarpa  M, Iovannitti  CA, et al. Sporothrix brasiliensis: a review of an emerging South American fungal pathogen, its related disease, presentation and spread in Argentina. J Fungi (Basel). 2021;7:170. DOIPubMedGoogle Scholar
  4. Cheng  S, Zheng  S, Zhong  M, Gyawali  KR, Pan  W, Xu  M, et al. Current situation of sporotrichosis in China. Future Microbiol. 2024;19:1097–106. DOIPubMedGoogle Scholar
  5. Rudramurthy  SM, Shankarnarayan  SA, Hemashetter  BM, Verma  S, Chauhan  S, Nath  R, et al. Phenotypic and molecular characterisation of Sporothrix globosa of diverse origin from India. Braz J Microbiol. 2021;52:91–100. DOIPubMedGoogle Scholar
  6. Yingchanakiat  K, Limsivilai  O, Sunpongsri  S, Niyomtham  W, Lugsomya  K, Yurayart  C. Phenotypic and genotypic characterization and antifungal susceptibility of Sporothrix schenckii sensu stricto isolated from a feline sporotrichosis outbreak in Bangkok, Thailand. J Fungi (Basel). 2023;9:590. DOIPubMedGoogle Scholar
  7. Langsiri  N, Banlunara  W, Klaychontee  O, Worasilchai  N, Cognialli  R, Queiroz-Telles  F, et al. Targeted long-read sequencing analysis and antifungal susceptibility profiles of Sporothrix schenckii isolates from Thailand. PLoS Negl Trop Dis. 2025;19:e0013253. DOIPubMedGoogle Scholar
  8. Indoung  S, Chanchayanon  B, Chaisut  M, Buapeth  KO, Morteh  R, Jantrakajorn  S. Feline sporotrichosis caused by Sporothrix schenckii sensu stricto in Southern Thailand: phenotypic characterization, molecular identification, and antifungal susceptibility. Med Mycol. 2022;60:myac075. DOIPubMedGoogle Scholar
  9. Gremião  ID, Miranda  LH, Reis  EG, Rodrigues  AM, Pereira  SA. Zoonotic epidemic of sporotrichosis: cat to human transmission. PLoS Pathog. 2017;13:e1006077. DOIPubMedGoogle Scholar
  10. Jirawattanadon  P, Bunyaratavej  S, Leeyaphan  C, Chongtrakool  P, Sitthinamsuwan  P, Panjapakkul  W, et al. Clinical manifestations, antifungal drug susceptibility, and treatment outcomes for emerging zoonotic cutaneous sporotrichosis, Thailand. Emerg Infect Dis. 2024;30:2583–92. DOIPubMedGoogle Scholar
  11. Bernardes-Engemann  AR, Tomki  GF, Rabello  VBS, Almeida-Silva  F, Freitas  DFS, Gutierrez-Galhardo  MC, et al. Sporotrichosis caused by non-wild type Sporothrix brasiliensis strains. Front Cell Infect Microbiol. 2022;12:893501. DOIPubMedGoogle Scholar
  12. Waller  SB, Dalla Lana  DF, Quatrin  PM, Ferreira  MRA, Fuentefria  AM, Mezzari  A. Antifungal resistance on Sporothrix species: an overview. Braz J Microbiol. 2021;52:73–80. DOIPubMedGoogle Scholar
  13. Gremião  IDF, Miranda  LHM, Pereira-Oliveira  GR, Menezes  RC, Machado  ACS, Rodrigues  AM, et al. Advances and challenges in the management of feline sporotrichosis. Rev Iberoam Micol. 2022;39:61–7. DOIPubMedGoogle Scholar
  14. Gremião  IDF, Martins da Silva da Rocha E, Montenegro H, Carneiro AJB, Xavier MO, de Farias MR, et al. Guideline for the management of feline sporotrichosis caused by Sporothrix brasiliensis and literature revision. Braz J Microbiol. 2021;52:107–24. DOIPubMedGoogle Scholar
  15. Nakasu  CCT, Waller  SB, Ripoll  MK, Ferreira  MRA, Conceição  FR, Gomes  ADR, et al. Feline sporotrichosis: a case series of itraconazole-resistant Sporothrix brasiliensis infection. Braz J Microbiol. 2021;52:163–71. DOIPubMedGoogle Scholar
  16. Larsson  CE. Sporotrichosis and cryptococcosis. Presented at: World Small Animal Veterinary Association Congress; Mexico City, Mexico; 2005 May 11–14.
  17. Easterwood  LF, Harkin  KR, Rankin  AJ. Oral voriconazole therapy in cats with histoplasmosis yielded mild side effects and a favorable outcome. J Am Vet Med Assoc. 2023;261:1–5. DOIPubMedGoogle Scholar
  18. Aroonvuthiphong  V, Bangphoomi  N. Therapeutic alternatives for sporotrichosis induced by wild-type and non-wild-type Sporothrix schenckii through in vitro and in vivo assessment of enilconazole, isavuconazole, posaconazole, and terbinafine. Sci Rep. 2025;15:3230. DOIPubMedGoogle Scholar
  19. Indira  G. In vitro Antifungal susceptibility testing of 5 antifungal agents against dermatophytic species by CLSI (M38-A) micro dilution method. Clin Microbiol. 2014;3:1–5. DOIGoogle Scholar
  20. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 3rd ed. M38. Wayne (PA): The Institute; 2017.
  21. Espinel-Ingroff  A, Abreu  DPB, Almeida-Paes  R, Brilhante  RSN, Chakrabarti  A, Chowdhary  A, et al. Multicenter, international study of MIC/MEC Distributions for definition of epidemiological cutoff values for Sporothrix species identified by molecular methods. Antimicrob Agents Chemother. 2017;61:e01057–17. DOIPubMedGoogle Scholar
  22. Clinical and Laboratory Standards Institute. Principles and procedures for the development of epidemiological cutoff values for antifungal susceptibility testing. Wayne (PA): The Institute; 2016.
  23. Inpankaew  T, Sattasathuchana  P, Kengradomkij  C, Thengchaisri  N. Prevalence of toxoplasmosis in semi-domesticated and pet cats within and around Bangkok, Thailand. BMC Vet Res. 2021;17:252. DOIPubMedGoogle Scholar
  24. Hoffmann-Fezer  G, Mortelbauer  W, Hartmann  K, Mysliwietz  J, Thefeld  S, Beer  B, et al. Comparison of T-cell subpopulations in cats naturally infected with feline leukaemia virus or feline immunodeficiency virus. Res Vet Sci. 1996;61:222–6. DOIPubMedGoogle Scholar
  25. Zhang  M, Zhou  Z, Wang  D, Zhou  A, Song  G, Chen  X, et al. Comparative evaluation of Sensititre YeastOne and VITEK 2 against the clinical and laboratory standards institute M27-E4 reference broth microdilution method for the antifungal susceptibility testing of Cryptococcus neoformans and Cryptococcus gattii. Med Mycol. 2022;60:myac009. DOIPubMedGoogle Scholar
  26. Alvarado-Ramírez  E, Torres-Rodríguez  JM. In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods. Antimicrob Agents Chemother. 2007;51:2420–3. DOIPubMedGoogle Scholar
  27. Tan  XT, Ginsapu  SJ. Amran Fb, Sukur SbM, Shukor Sb. Susceptibility of filamentous fungi to voriconazole in Malaysia tested by Sensititre YeastOne and CLSI mirocilution methods. Research Square. 2021;.DOIGoogle Scholar
  28. Pfaller  MA, Diekema  DJ. Progress in antifungal susceptibility testing of Candida spp. by use of clinical and laboratory standards institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50:2846–56. DOIPubMedGoogle Scholar
  29. Espinel-Ingroff  A, Cuenca-Estrella  M, Fothergill  A, Fuller  J, Ghannoum  M, Johnson  E, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:5150–4. DOIPubMedGoogle Scholar
  30. Mawby  DI, Whittemore  JC, Fowler  LE, Papich  MG. Comparison of absorption characteristics of oral reference and compounded itraconazole formulations in healthy cats. J Am Vet Med Assoc. 2018;252:195–200. DOIPubMedGoogle Scholar
  31. Lloret  A, Hartmann  K, Pennisi  MG, Ferrer  L, Addie  D, Belák  S, et al. Sporotrichosis in cats: ABCD guidelines on prevention and management. J Feline Med Surg. 2013;15:619–23. DOIPubMedGoogle Scholar
  32. Kelly  SL, Lamb  DC, Kelly  DE, Manning  NJ, Loeffler  J, Hebart  H, et al. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett. 1997;400:80–2. DOIPubMedGoogle Scholar
  33. Vazquez  JA, Arganoza  MT, Boikov  D, Yoon  S, Sobel  JD, Akins  RA. Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles. J Clin Microbiol. 1998;36:2690–5. DOIPubMedGoogle Scholar
  34. Kauffman  CA, Bustamante  B, Chapman  SW, Pappas  PG; Infectious Diseases Society of America. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:1255–65. DOIPubMedGoogle Scholar
  35. Gremião  I, Schubach  T, Pereira  S, Rodrigues  A, Honse  C, Barros  M. Treatment of refractory feline sporotrichosis with a combination of intralesional amphotericin B and oral itraconazole. Aust Vet J. 2011;89:346–51. DOIPubMedGoogle Scholar
  36. Francesconi  G, Francesconi do Valle  AC, Passos  SL, de Lima Barros  MB, de Almeida Paes  R, Curi  AL, et al. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Mycopathologia. 2011;171:349–54. DOIPubMedGoogle Scholar
  37. Viana  PG, Figueiredo  ABF, Gremião  IDF, de Miranda  LHM, da Silva Antonio  IM, Boechat  JS, et al. Successful treatment of canine sporotrichosis with terbinafine: case reports and literature review. Mycopathologia. 2018;183:471–8. DOIPubMedGoogle Scholar
  38. Viana  PG, Gremião  IDF, da Silva Antonio  IM, Figueiredo  ABF, Correa  ML, Boechat  JS, et al. Is terbinafine an effective treatment for feline sporotrichosis? Vet Rec. 2024;195:e4435. DOIPubMedGoogle Scholar

Main Article

Page created: April 29, 2026
Page updated: May 21, 2026
Page reviewed: May 21, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external